These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 21527360

  • 1. Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity?
    Schuuring MJ, Vis JC, Bouma BJ, van Dijk AP, van Melle JP, Pieper PG, Vliegen HW, Sieswerda GT, Mulder BJ.
    Contemp Clin Trials; 2011 Jul; 32(4):586-91. PubMed ID: 21527360
    [Abstract] [Full Text] [Related]

  • 2. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
    Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K, Sørensen KE, Søndergaard L.
    Circulation; 2014 Dec 02; 130(23):2021-30. PubMed ID: 25446057
    [Abstract] [Full Text] [Related]

  • 3. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.
    Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin-Bon RH, Mulder BJ, Bouma BJ.
    Eur J Heart Fail; 2013 Jun 02; 15(6):690-8. PubMed ID: 23361871
    [Abstract] [Full Text] [Related]

  • 4. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2005 Nov 02; 91(11):1447-52. PubMed ID: 15761050
    [Abstract] [Full Text] [Related]

  • 5. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2007 Mar 02; 93(3):350-4. PubMed ID: 16980516
    [Abstract] [Full Text] [Related]

  • 6. Relation of systemic venous return, pulmonary vascular resistance, and diastolic dysfunction to exercise capacity in patients with single ventricle receiving fontan palliation.
    Goldstein BH, Connor CE, Gooding L, Rocchini AP.
    Am J Cardiol; 2010 Apr 15; 105(8):1169-75. PubMed ID: 20381672
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of endothelin blockade in adults with Fontan physiology.
    Derk G, Houser L, Miner P, Williams R, Moriarty J, Finn P, Alejos J, Aboulhosn J.
    Congenit Heart Dis; 2015 Apr 15; 10(1):E11-6. PubMed ID: 24890846
    [Abstract] [Full Text] [Related]

  • 8. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M, Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.
    Circulation; 2006 Jul 04; 114(1):48-54. PubMed ID: 16801459
    [Abstract] [Full Text] [Related]

  • 9. Impact of vitamin C on endothelial function and exercise capacity in patients with a Fontan circulation.
    Goldstein BH, Sandelin AM, Golbus JR, Warnke N, Gooding L, King KK, Donohue JE, Yu S, Gurney JG, Goldberg CS, Rocchini AP, Charpie JR.
    Congenit Heart Dis; 2012 Jul 04; 7(3):226-34. PubMed ID: 22176653
    [Abstract] [Full Text] [Related]

  • 10. The safety and effects of bosentan in patients with a Fontan circulation.
    Bowater SE, Weaver RA, Thorne SA, Clift PF.
    Congenit Heart Dis; 2012 Jul 04; 7(3):243-9. PubMed ID: 22348734
    [Abstract] [Full Text] [Related]

  • 11. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation.
    Apostolopoulou SC, Papagiannis J, Rammos S.
    J Heart Lung Transplant; 2005 Aug 04; 24(8):1174-6. PubMed ID: 16102469
    [Abstract] [Full Text] [Related]

  • 12. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ, Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group.
    J Am Coll Cardiol; 2008 Dec 16; 52(25):2127-34. PubMed ID: 19095129
    [Abstract] [Full Text] [Related]

  • 13. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD, Franks C, O'Brien K, Seale H, Hall K, McNeil K, Radford D.
    Heart Lung Circ; 2010 Oct 16; 19(10):595-600. PubMed ID: 20728407
    [Abstract] [Full Text] [Related]

  • 14. The effect of bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study.
    Hebert A, Jensen AS, Idorn L, Sørensen KE, Søndergaard L.
    BMC Cardiovasc Disord; 2013 May 11; 13():36. PubMed ID: 23663658
    [Abstract] [Full Text] [Related]

  • 15. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP, Humbert M, Rubin L, Black CM.
    Ann Rheum Dis; 2006 Oct 11; 65(10):1336-40. PubMed ID: 16793845
    [Abstract] [Full Text] [Related]

  • 16. Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia.
    Faoro V, Boldingh S, Moreels M, Martinez S, Lamotte M, Unger P, Brimioulle S, Huez S, Naeije R.
    Chest; 2009 May 11; 135(5):1215-1222. PubMed ID: 19188550
    [Abstract] [Full Text] [Related]

  • 17. The effect of bosentan in patients with a failing Fontan circulation.
    Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L.
    Cardiol Young; 2009 Aug 11; 19(4):331-9. PubMed ID: 19519964
    [Abstract] [Full Text] [Related]

  • 18. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.
    Eur J Clin Invest; 2006 Sep 11; 36 Suppl 3():25-31. PubMed ID: 16919007
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    Monfredi O, Griffiths L, Clarke B, Mahadevan VS.
    Am J Cardiol; 2011 Nov 15; 108(10):1483-8. PubMed ID: 21943933
    [Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of bosentan in adults with Eisenmenger physiology.
    Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, Mikhail GW, Gibbs JS.
    Int J Cardiol; 2005 Jan 15; 98(1):147-51. PubMed ID: 15676179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.